


# Global NIT study group

## 6 cohorts:

2 population-based

1 at-risk cohort

3 tertiary care



# SLD cACLD + HVPG (Baveno)



405 MASLD


136 MetALD

155 ALD

(Semmler & Francque  
& Hernandez-Gea)

~1800 cACLD

(Berzigotti & Mandorfer)



# MASLD decompensated cirrhosis (Baveno)

